drugset / Trial / NCT00253214
Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the safety and effectiveness of a once daily controlled-release form of galantamine (a drug for treating dementia) versus placebo in the treatment of patients with Alzheimer's disease.
Timeline
- Start
- 2001-03
- Primary completion
- —
- Completion
- 2002-07
Publications
- Results Brodaty H, Corey-Bloom J, Potocnik FC, Truyen L, Gold M, Damaraju CR. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord. 2005;20(2-3):120-32. doi: 10.1159/000086613. Epub 2005 Jun 30.
- Lim AWY, Schneider L, Loy C. Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev. 2024 Nov 5;11(11):CD001747. doi: 10.1002/14651858.CD001747.pub4.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Galantamine | Small molecule | 4 mg | Oral |
| Subject | Galantamine | Small molecule | 8 mg | Oral |
| Subject | Galantamine | Small molecule | 12 mg | Oral |
| Subject | Galantamine | Small molecule | 24 mg | Oral |